No results found for “”
No results found for filter “”
-
Statements & press releases 26.11.24
Urgent policy reforms needed to support the future of Europe’s biopharma SMEs, says EFPIA
SMEs are critical to the future of European life sciences and patients. We need policymakers to get behind an ambitious strategic vision for the competitiveness...
Read Article -
Blog articles 20.11.24
European Antibiotic Awareness Day: Urgent Need for Sustainable Antimicrobial R&D to Combat Superbugs
In Europe alone, antimicrobial resistance or AMR results in 35,000 deaths annually, with healthcare costs and productivity losses estimated at €1.5 billion...
Read Article -
EFPIA News 18.11.24
Breaking barriers in Rare Disease Research: The Rare Disease Moonshot at two years
Rare diseases impact millions globally, yet fewer than 5% of the over 7,000 identified have treatments, underscoring an urgent need for action. The Rare...
Read Article -
Blog articles 14.11.24
INNODIA: A Success Story in Type 1 Diabetes Research and Treatment (Guest blog)
Type 1 Diabetes (T1D) is an autoimmune disease where the body’s own immune system mistakenly attacks insulin-producing beta cells in the pancreas. It’s...
Read Article -
Statements & press releases 13.11.24
Despite a decade of gradual growth, R&D spending in Europe outpaced by the US – with increasing competition...
Boosting European competitiveness to kickstart growth requires concerted, collective action; urgent implementation of a coherent life sciences strategy...
Read Article -
Blog articles 13.11.24
Filling the Gaps in Care: Driving Change through Embracing Carers® (Guest blog)
Supporting informal carers isn’t just about helping; it’s about elevating entire communities.
Read Article -
Blog articles 10.11.24
Navigating Certainty and Analytical Complexity: Industry’s Reflections on Ensuring Scientific Rigor and...
The HTA Regulation (HTAR) requires that Joint Clinical Assessments (JCAs) describe the certainty of a health technology’s effects by considering the strengths...
Read Article -
Statements & press releases 05.11.24
Joint statement from the human pharmaceutical industry on the Urban Wastewater Treatment Directive (UWWTD)...
EFPIA and AESGP, representing the human pharmaceutical industry in Europe, acknowledge, with some reservations, the approval by the Council of the European...
Read Article -
Blog articles 29.10.24
Around the world of evidence synthesis (in eighty pages): the methodological and practical guidelines...
Application of the European HTA Regulation is around the corner - in only a few months from now, the first products will go through the new European Joint...
Read Article -
Blog articles 28.10.24
Chasing bold goals to unlock new solutions
Learn more about Timothy Radstake, Vice President and Global Head of Immunology Discovery Research at AbbVie, and his efforts to drive innovation, close...
Read Article -
Blog articles 24.10.24
Let’s dig deeper on Unmet Medical Need (Guest Blog)
Stefan Frings explains why a broad, encompassing definition of Unmet Medical Need, is key in R&D investment decisions.
Read Article -
Blog articles 23.10.24
Overcoming the barriers to Europe’s leadership in medical innovation
Over the years, Europe’s share of global medicine R&D investments has dropped. However, with the new EU mandate, there is a chance to turn this around......
Read Article
No results found for “”
No results found for filter “”
-
EFPIA News 18.11.24
Breaking barriers in Rare Disease Research: The Rare Disease Moonshot at two years
Rare diseases impact millions globally, yet fewer than 5% of the over 7,000 identified have treatments, underscoring an urgent need for action. The Rare...
Read Article -
EFPIA News 26.09.24
EFPIA position on opt-out in the EHDS Regulation
EFPIA stresses the importance of avoiding fragmentation and bias, clarifying the scope of the opt-out by limiting it to personal data and creating a centralised...
Read Article -
EFPIA News 11.07.24
NIRO: Navigating innovation and research opportunities
A new tool to help navigate the complex world of health R&I funding programmes.
Read Article -
EFPIA News 08.07.24
Breaking down barriers: Making cross-border access to clinical trials a reality
Collaborative effort by EFGCP and EFPIA develops action plan to address participation barriers in Europe
Read Article -
EFPIA News 12.06.24
New data from EFPIA reveals multiple factors leading to unequal access to medicines for patients across...
"Whatever the reason, whatever the cause, we stand ready to play our part in reducing the time it takes for patients to access the medicines we discover,...
Read Article -
EFPIA News 04.06.24
Insights from EFPIA's Reliance Webinar
On the 19th of March EFPIA have hosted a joint industry webinar on Reliance, providing a platform for information and discussion on use of EMA assessment...
Read Article -
EFPIA News 26.04.24
Journal article - Evolving assessment pathways for precision oncology medicines to improve patient access:...
This study describes challenges in assessing PO and TA medicines, explores possible solutions, and provides actionable recommendations to facilitate an...
Read Article -
EFPIA News 26.04.24
White paper on circular economy
Continued adoption of circular economy principles into the pharmaceutical sector can reduce materials extraction and operational waste, contribute to a...
Read Article -
EFPIA News 28.03.24
NIRO: Navigating Innovation & Research Opportunities
NIRO helps you find available European and international funds for research & innovation.
Read Article -
EFPIA News 13.02.24
European business calls for deepening the EU Single Market and renewing the dynamic of European integration...
Read the joint statement from 26 trade associations.
Read Article -
EFPIA News 06.02.24
Recording Now Available: EJP RD-EFPIA Joint Advanced Webinar on Real-World Data, Machine Learning, and...
...
Read Article -
EFPIA News 27.10.23
Stefan Oelrich's interview at the POLITICO Health Care Summit
Watch the recording.
Read Article
No results found for “”
No results found for filter “”
-
Statements & press releases 26.11.24
Urgent policy reforms needed to support the future of Europe’s biopharma SMEs, says EFPIA
SMEs are critical to the future of European life sciences and patients. We need policymakers to get behind an ambitious strategic vision for the competitiveness...
Read Article -
Statements & press releases 13.11.24
Despite a decade of gradual growth, R&D spending in Europe outpaced by the US – with increasing competition...
Boosting European competitiveness to kickstart growth requires concerted, collective action; urgent implementation of a coherent life sciences strategy...
Read Article -
Statements & press releases 05.11.24
Joint statement from the human pharmaceutical industry on the Urban Wastewater Treatment Directive (UWWTD)...
EFPIA and AESGP, representing the human pharmaceutical industry in Europe, acknowledge, with some reservations, the approval by the Council of the European...
Read Article -
Statements & press releases 22.10.24
60,000 fewer clinical trial places for Europeans, despite global surge in research projects.
"For Europe to be competitive, it needs to function as a unified region" says Nathalie Moll.
Read Article -
Statements & press releases 18.10.24
EFPIA position on the Urban Wastewater Treatment Directive
EFPIA, its member companies and national associations are concerned by the impact that the Urban Wastewater Treatment Directive will have on European patients...
Read Article -
Statements & press releases 16.10.24
Coalition of 43 Business Associations Rallies Behind Call for Bold & Open Trade Policy to Keep Europe...
As the European Parliament prepares for the confirmation hearings of the new Commissioners, the Open Trade Coalition is reiterating its call for a bold...
Read Article -
Statements & press releases 17.09.24
EFPIA responds to the announcement of the College of Commissioners and publication of their mission letters...
EFPIA, Vaccines Europe and our members congratulate all the Commissioner-designates on their proposed roles.
Read Article -
Statements & press releases 09.09.24
EFPIA response to Mario Draghi EU competitiveness report
EFPIA welcomes recognition of the innovative pharmaceutical sector’s importance to EU competitiveness and calls for swift adoption of the recommendations....
Read Article -
Statements & press releases 02.09.24
Thomas Gelin joins EFPIA as Executive Director, International Affairs
With Europe’s competitive edge at the top of the political agenda, EFPIA is delighted to announce the appointment of Thomas Gelin as Executive Director,...
Read Article -
Statements & press releases 24.07.24
EFPIA position on EHDS
The EHDS will require the public and private sectors to work together in new and innovative ways. We look forward to working with the EU institutions and...
Read Article -
Statements & press releases 18.07.24
EFPIA Response to the publication of Political Guidelines for the Next European Commission 2024-2029
The dedicated life sciences strategy is an important part of the wider drive to boost European competitiveness over the next five years.
Read Article -
Statements & press releases 04.07.24
Joint Statement for an Ambitious FP10
Investing in Europe’s Future Competitiveness through Collaborative Research, Development, and Innovation
Read Article
No results found for “”
No results found for filter “”
-
Blog articles 20.11.24
European Antibiotic Awareness Day: Urgent Need for Sustainable Antimicrobial R&D to Combat Superbugs
In Europe alone, antimicrobial resistance or AMR results in 35,000 deaths annually, with healthcare costs and productivity losses estimated at €1.5 billion...
Read Article -
Blog articles 14.11.24
INNODIA: A Success Story in Type 1 Diabetes Research and Treatment (Guest blog)
Type 1 Diabetes (T1D) is an autoimmune disease where the body’s own immune system mistakenly attacks insulin-producing beta cells in the pancreas. It’s...
Read Article -
Blog articles 13.11.24
Filling the Gaps in Care: Driving Change through Embracing Carers® (Guest blog)
Supporting informal carers isn’t just about helping; it’s about elevating entire communities.
Read Article -
Blog articles 10.11.24
Navigating Certainty and Analytical Complexity: Industry’s Reflections on Ensuring Scientific Rigor and...
The HTA Regulation (HTAR) requires that Joint Clinical Assessments (JCAs) describe the certainty of a health technology’s effects by considering the strengths...
Read Article -
Blog articles 29.10.24
Around the world of evidence synthesis (in eighty pages): the methodological and practical guidelines...
Application of the European HTA Regulation is around the corner - in only a few months from now, the first products will go through the new European Joint...
Read Article -
Blog articles 28.10.24
Chasing bold goals to unlock new solutions
Learn more about Timothy Radstake, Vice President and Global Head of Immunology Discovery Research at AbbVie, and his efforts to drive innovation, close...
Read Article -
Blog articles 24.10.24
Let’s dig deeper on Unmet Medical Need (Guest Blog)
Stefan Frings explains why a broad, encompassing definition of Unmet Medical Need, is key in R&D investment decisions.
Read Article -
Blog articles 23.10.24
Overcoming the barriers to Europe’s leadership in medical innovation
Over the years, Europe’s share of global medicine R&D investments has dropped. However, with the new EU mandate, there is a chance to turn this around......
Read Article -
Blog articles 15.10.24
Advancing the precision oncology agenda in the EU: developing a roadmap at country level to address the...
Access to precision oncology is essential to ensure optimal and timely treatment of patients with cancer. However, challenges to access precision oncology...
Read Article -
Blog articles 08.10.24
‘I may have Alzheimer’s, but it doesn’t have me.’
What do patients want? Quality time with loved ones and hope for a meaningful life after diagnosis
Read Article -
Blog articles 03.10.24
How the EU can incentivise environmental sustainability of new medicines
Europe’s medicines sector is making real progress on sustainability – this should be reflected in the EU Taxonomy on sustainable investment
Read Article -
Blog articles 26.09.24
Establishing criteria for unmet medical needs: let’s not leave people living with chronic diseases behind...
The narrow definition of unmet medical need used in the General Pharmaceutical Legislation may hinder rather than help efforts to find new treatments.
Read Article